×

Predictors Of Patient Response To Treatment With EGFR Inhibitors

  • US 20070128636A1
  • Filed: 12/04/2006
  • Published: 06/07/2007
  • Est. Priority Date: 12/05/2005
  • Status: Abandoned Application
First Claim
Patent Images

1. A method for predicting the response of a subject diagnosed with EGFR positive cancer to treatment with an EGFR inhibitor, comprising determining the expression level of one or more RNA transcripts or their expression products in a biological sample containing cancer cells obtained from said subject, wherein the RNA transcript is of one or more genes selected from the group consisting of (i) genes located near EGFR on chromosome 7p11.2, (ii) ERBB2 and genes located near ERBB2 on chromosome 12q.13, (iii) ERBB3 and genes located near ERBB3 on chromosome 17q21.1;

  • (iv) ERBB4 and genes located near ERBB4 on chromosome 7p11.2;

    (v) genes involved in ADCC and gene markers of immune or inflammatory cells;

    (vi) genes associated with tumor cell invasion; and

    (vii) genes characteristic of late stage tumors, wherein (a) for every unit of increased expression of one or more genes selected from groups (i), (ii), (iii), (iv), and (v), or the corresponding expression product, said subject is predicted to have an increased likelihood of response to treatment with said EGFR inhibitor; and

    (b) for every unit of increased expression of one or more genes selected from group (vi) or group (vii), or the corresponding expression product, said subject is predicted to have a decreased likelihood of response to treatment with said EGFR inhibitor.

View all claims
  • 1 Assignment
Timeline View
Assignment View
    ×
    ×